Literature DB >> 16631077

Nicotinic alpha4beta2 receptor imaging agents: part II. Synthesis and biological evaluation of 2-[18F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (18F-nifene) in rodents and imaging by PET in nonhuman primate.

Rama Pichika1, Balasubramaniam Easwaramoorthy, Daphne Collins, Bradley T Christian, Bingzhi Shi, Tanjore K Narayanan, Steven G Potkin, Jogeshwar Mukherjee.   

Abstract

The alpha4beta2 nicotinic acetylcholine receptor (nAChR) has been implicated in various neurodegenerative diseases. Optimal positron emission tomography (PET) imaging agents are therefore highly desired for this receptor. We report here the development and initial evaluation of 2-fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (nifene). In vitro binding affinity of nifene in rat brain homogenate using 3H-cytisine exhibited a K(i) = 0.50 nM for the alpha4beta2 sites. The radiosynthesis of 2-18F-fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (18F-nifene) was accomplished in 2.5 h with an overall radiochemical yield of 40-50%, decay corrected. The specific activity was estimated to be approx. 37-185 GBq/micromol. In vitro autoradiography in rat brain slices indicated selective binding of 18F-nifene to anteroventral thalamic (AVT) nucleus, thalamus, subiculum, striata, cortex and other regions consistent with alpha4beta2 receptor distribution. Rat cerebellum showed some binding, whereas regions in the hippocampus had the lowest binding. The highest ratio of >13 between AVT and cerebellum was measured for 18F-nifene in rat brain slices. The specific binding was reduced (>95%) by 300 microM nicotine in these brain regions. Positron emission tomography imaging study of 18F-nifene (130 MBq) in anesthetized rhesus monkey was carried out using an ECAT EXACT HR+ scanner. PET study showed selective maximal uptake in the regions of the anterior medial thalamus, ventro-lateral thalamus, lateral geniculate, cingulate gyrus, temporal cortex including the subiculum. The cerebellum in the monkeys showed lower binding than the other regions. Thalamus-to-cerebellum ratio peaked at 30-35 min postinjection to a value of 2.2 and subsequently reduced. The faster binding profile of 18F-nifene indicates promise as a PET imaging agent and thus needs further evaluation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631077     DOI: 10.1016/j.nucmedbio.2005.12.017

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  26 in total

1.  Nicotinic α4β2 receptor imaging agents. Part III. Synthesis and biological evaluation of 3-(2-(S)-azetidinylmethoxy)-5-(3'-18F-fluoropropyl)pyridine (18F-nifzetidine).

Authors:  Rama Pichika; Balu Easwaramoorthy; Bradley T Christian; Bingzhi Shi; Tanjore K Narayanan; Daphne Collins; Jogeshwar Mukherjee
Journal:  Nucl Med Biol       Date:  2011-08-09       Impact factor: 2.408

2.  Specific α4β2 nicotinic acetylcholine receptor binding of [F-18]nifene in the rhesus monkey.

Authors:  A T Hillmer; D W Wooten; J M Moirano; M Slesarev; T E Barnhart; J W Engle; R J Nickles; D Murali; M L Schneider; J Mukherjee; B T Christian
Journal:  Synapse       Date:  2011-08-31       Impact factor: 2.562

3.  [18 F]Nifene test-retest reproducibility in first-in-human imaging of α4β2* nicotinic acetylcholine receptors.

Authors:  Patrick J Lao; Tobey J Betthauser; Dana L Tudorascu; Todd E Barnhart; Ansel T Hillmer; Charles K Stone; Jogeshwar Mukherjee; Bradley T Christian
Journal:  Synapse       Date:  2017-04-26       Impact factor: 2.562

4.  Nicotinic α4β2 receptor imaging agents. Part IV. Synthesis and biological evaluation of 3-(2-(S)-3,4-dehydropyrrolinyl methoxy)-5-(3'-¹⁸F-fluoropropyl)pyridine (¹⁸F-Nifrolene) using PET.

Authors:  Rama Pichika; Sharon A Kuruvilla; Narmisha Patel; Kenny Vu; Sangamitra Sinha; Balu Easwaramoorthy; Tanjore K Narayanan; Bingzhi Shi; Bradley Christian; Jogeshwar Mukherjee
Journal:  Nucl Med Biol       Date:  2012-11-07       Impact factor: 2.408

5.  Development of fluorescence imaging probes for nicotinic acetylcholine α4β2 receptors.

Authors:  Gurleen K Samra; Irakli Intskirveli; Anitha P Govind; Christopher Liang; Ronit Lazar; William N Green; Raju Metherate; Jogeshwar Mukherjee
Journal:  Bioorg Med Chem Lett       Date:  2017-12-17       Impact factor: 2.823

6.  Nicotinic acetylcholine receptors in rat forebrain that bind ¹⁸F-nifene: relating PET imaging, autoradiography, and behavior.

Authors:  Kasia M Bieszczad; Ritu Kant; Cristian C Constantinescu; Suresh K Pandey; Hideki D Kawai; Raju Metherate; Norman M Weinberger; Jogeshwar Mukherjee
Journal:  Synapse       Date:  2012-02-15       Impact factor: 2.562

7.  Human brain imaging of nicotinic acetylcholine α4β2* receptors using [18 F]Nifene: Selectivity, functional activity, toxicity, aging effects, gender effects, and extrathalamic pathways.

Authors:  Jogeshwar Mukherjee; Patrick J Lao; Tobey J Betthauser; Gurleen K Samra; Min-Liang Pan; Ishani H Patel; Christopher Liang; Raju Metherate; Bradley T Christian
Journal:  J Comp Neurol       Date:  2017-09-19       Impact factor: 3.215

8.  Imaging α4β2 Nicotinic Acetylcholine Receptors (nAChRs) in Baboons with [18F]XTRA, a Radioligand with Improved Specific Binding in Extra-Thalamic Regions.

Authors:  Hiroto Kuwabara; Yongjun Gao; Michael Stabin; Jennifer Coughlin; Sridhar Nimmagadda; Robert F Dannals; Martin G Pomper; Andrew G Horti
Journal:  Mol Imaging Biol       Date:  2017-04       Impact factor: 3.488

9.  The effects of lobeline on α4β2* nicotinic acetylcholine receptor binding and uptake of [(18)F]nifene in rats.

Authors:  Ansel T Hillmer; Dustin W Wooten; Mohammed Farhoud; Todd E Barnhart; Jogeshwar Mukherjee; Bradley T Christian
Journal:  J Neurosci Methods       Date:  2013-01-28       Impact factor: 2.390

10.  The hippocampus and cingulate cortex differentially mediate the effects of nicotine on learning versus on ethanol-induced learning deficits through different effects at nicotinic receptors.

Authors:  Danielle Gulick; Thomas J Gould
Journal:  Neuropsychopharmacology       Date:  2009-04-29       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.